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Abstract
Aims/hypothesis We examined the associations between de-
pressive symptoms and diabetes distress with glycaemic con-
trol and diabetes complications over 2 years, after diagnosis of
type 2 diabetes.
Methods In a multi-ethnic, primary care cohort (n = 1735) of
adults, all with recent (<6 months) diagnosis of type 2 diabe-
tes, we measured the associations between depressive symp-
toms (Patient Health Questionnaire-9 [PHQ-9] score ≥10) and
diabetes distress (Problem Areas in Diabetes [PAID] score
≥40), with change in 2 year HbA1c as the primary outcome
and with incident rates of diabetes complications as secondary
outcomes. Multivariate models were used to account for po-
tential confounders.
Results Of the 1651 participants (95.2%) of the total primary
care cohort with available baseline PHQ-9 and PAID scores,
mean ± SD age was 56.2 ± 11.1 years, 55.1% were men and
49.1% were of non-white ethnicity; 232 (14.1%) and 111
(6.7%) had depressive symptoms and diabetes distress, respec-
tively. After adjustment for confounders, depressive symptoms
were not associated with worsening HbA1c. After adjustment
for age, sex, ethnicity, vascular risk factors and diabetes treat-
ments, depressive symptoms were associated with increased
risk of incident macrovascular complications (OR 2.78 [95%
CI 1.19, 6.49], p = 0.018) but not microvascular complications.
This was attenuated (p = 0.09) after adjustment for IL-1 recep-
tor antagonist concentration. Diabetes distress was not associ-
ated with worsening HbA1c or incident complications.
Conclusions/interpretation In the first 2 years of type 2 dia-
betes, the effect of depressive symptoms and diabetes distress
on glycaemic control is minimal. There was, however, an
association between depressive symptoms and incidence of
macrovascular complications. Elevated innate inflammation
may be common to both depression and macrovascular
diabetes complications, but these findings require replication.
Keywords Depressive symptoms . Diabetes distress .
Glycaemic control . Inflammation .Macrovascular
complications .Microvascular complications .Type2diabetes
Abbreviations
CABG Coronary artery bypass graft
GP General practitioner
IL-1RA IL-1 receptor antagonist
IMD Index of multiple deprivation
IQR Interquartile range
LSOA Lower Super Output Area
MI Myocardial infarction
PAID Problem Areas in Diabetes
PHQ-9 Patient Health Questionnaire-9
SOUL-D South London Diabetes
Daniel Stahl and Stephanie A. Amiel are joint senior authors.
* Khalida Ismail
khalida.2.ismail@kcl.ac.uk
1 Department of Psychological Medicine, Institute of Psychiatry,
Psychology and Neuroscience, King’s College London, London SE5
9RJ, UK
2 Division of Diabetes and Nutritional Sciences, Faculty of Life
Sciences and Medicine, King’s College London, London, UK
3 Department of Diabetes and Endocrinology, Guy’s & St Thomas’
NHS Foundation Trust, London, UK
4 Department of Clinical Biochemistry, King’s College Hospital NHS
Foundation Trust, London, UK
5 Department of Biostatistics, Institute of Psychiatry, Psychology and
Neuroscience, King’s College London, London, UK
Diabetologia
DOI 10.1007/s00125-017-4367-3
Introduction
Depressive symptoms are associated with worse outcomes in
the natural history of type 2 diabetes mellitus and are associ-
ated with an approximately 60% increased risk of incident
disease; conversely, type 2 diabetes increases the risk of inci-
dent depressive symptoms by approximately 20% [1, 2]. In
established type 2 diabetes, depressive symptoms are associ-
ated with a 1.5- to threefold increased risk of diabetes compli-
cations and premature mortality [3–5]. The reasons for the
adverse effects of depressive symptoms in type 2 diabetes
are incompletely understood. A psychological explanation is
frequently cited for the relationship, namely that depressive
symptoms such as low mood and anhedonia (loss of pleasure
in everyday activities) lead to neglect of diabetes self-
management and consequent worse glycaemic control [6, 7].
However, pooled data from cross-sectional studies of depres-
sive symptoms and glycaemic control have found only a small
effect size (d = 0.17) [8]. From the few prospective studies
published, the evidence for an association between depressive
symptoms and glycaemic control is also weak [9–13]. While
treatments for depressive symptoms usually improve depres-
sive symptoms [14, 15], they do not always improve
glycaemic control, unless integrated with additional support
in diabetes management [16]. This suggests that other mech-
anisms may also underlie the association between depressive
symptoms and type 2 diabetes.
An alternative psychological mechanism is diabetes distress.
Diabetes distress is distinguished from depression by referring
to the burdens, worries and fears specific to people living with
diabetes. Measures of diabetes distress, such as the Problem
Areas in Diabetes (PAID) scale [17], show moderate-to-strong
correlations with self-report measures of depressive symptoms.
However, a large part of the variance in such scales is not
explained by depressive symptoms [18]. For example, a longi-
tudinal study of 1567 individuals with diabetes found that 55%
of those with diabetes distress did not have likely depression
[19], while a factor analysis study reported that depression and
distress symptoms could be segregated into two independent
factors [20]. Clinically, diabetes distress is significant because it
may be a greater psychological barrier to self-management, and
therefore to optimising glycaemic control, than depressive
symptoms [21, 22] and it is potentially modifiable using psy-
chological therapy [23]. To date, we are aware of only one
observational study that has compared depressive symptoms
and diabetes distress prospectively in type 2 diabetes, reporting
that diabetes distress had a greater effect on worsening
glycaemic control than on depressive symptoms [9]. We are
not aware of a longitudinal study of the independent effect of
diabetes distress on increased risk for diabetes complications.
The prevalence of depressive symptoms and diabetes dis-
tress are known to increase with diabetes duration [24, 25], an
important confounder that limits the interpretation of previous
studies of the effects of depression and diabetes distress on
self-management and glycaemic control [11, 26]. Studying
these potential effects at the time of diagnosis of type 2 dia-
betes is a methodologically robust approach, as there is min-
imal confounding by long duration of type 2 diabetes and it is
an important window of opportunity for interventions.
We therefore conducted a multi-ethnic cohort study in pri-
mary care to test and compare the associations of depressive
symptoms and diabetes distress with change in glycaemic
control as the primary outcome, as well as incidence of
macro- andmicrovascular complications as the secondary out-
comes, in people with newly diagnosed type 2 diabetes.
Methods
Design
The South London Diabetes (SOUL-D) study is a population-
based, primary care prospective cohort of people with newly
diagnosed type 2 diabetes recruited within 6 months of diag-
nosis and followed up after 1 and 2 years. Ethical approval
was granted by the King’s College Hospital Research Ethics
Committee (reference 08/H0808/1) and by Lambeth,
Southwark and Lewisham Primary Care Trusts (reference
RDLSLB 410). All participants gave written informed con-
sent, including for allowing access to their medical records.
Setting
The study was set in the inner-city boroughs of Lambeth,
Southwark and Lewisham in South London, UK, which col-
lectively have approximately 0.75 million residents from di-
verse socioeconomic and ethnic backgrounds [27]. All general
practitioner (GP) surgeries (n = 138) in these boroughs were
invited to participate. Local protocols for diagnosis of type 2
diabetes followed WHO criteria [28].
Study population and case definition
People with a recent (<6 months) diagnosis of type 2 diabetes,
aged 18–75 years at diagnosis, were identified from the man-
datory electronic diabetes registers of participating surgeries
and invited to participate. Exclusion criteria, derived from the
medical records, were: dementia, terminal illness, temporary
residence and residence outside the catchment area, other
types of diabetes and severe end-stage diabetes complications
defined as registered blind, receiving dialysis or previous
above-knee amputation. Recruitment was conducted between
May 2008 and April 2011 and follow-up ended August 2014;
further details of the sampling methodology have been de-
scribed in detail elsewhere [27]. The standardised data collec-
tion schedule at baseline consisted of a clinical examination,
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self-report questionnaires, venepuncture, urine analysis and
data extracted from routine medical records, all repeated at 1
and 2 years (±3 months).
Main outcomes
The primary outcome was HbA1c after 2 years, measured by
affinity chromatography (Primus Ultra2; Primus Diagnostics,
Kansas City, KS, USA) and reported in both DCCT-derived
(%) and IFCC (International Federation of Clinical Chemists)-
recommended units (mmol/mol). HbA1c was also measured at
1 year follow-up. If at follow-up there were missing HbA1c data
(participant uncontactable or did not want to attend), we used
HbA1c from the medical records if it had been collected
3 months before or after the scheduled date. Secondary out-
comes were incidence of macrovascular complications (any
myocardial infarction [MI], coronary artery bypass graft
[CABG], stroke or carotid/limb revascularisation or amputa-
tion, derived from the medical records) andmicrovascular com-
plications (neuropathy, assessed clinically at each study visit by
neurothesiometry vibration perception threshold ≥25 V; ne-
phropathy, defined as albumin–creatinine ratio ≥3 mg/mmol,
taken frommedical records; or retinopathy, assessed usingmed-
ical record retinal eye screen data, performed annually on all
residents with diabetes using digital two-field photography and
coded by trained graders as present or absent using the English
Retinopathy Minimum Grading System) during follow-up.
Main explanatory variables
Depressive symptoms were measured by the Patient Health
Questionnaire-9 (PHQ-9), a nine-item self-report measure
based on the Diagnostic and Statistical Manual-IV diagnostic
criteria for major depressive symptoms, with scores ranging
from 0 to 27. We used a cut-off score of ≥10 for identifying
depressive symptoms, as this has been found to have 88%
sensitivity and specificity for major depression compared with
clinical interview [29] and was validated in the SOUL-D co-
hort at baseline [30]. Diabetes distress was measured using the
PAID scale [17]. The PAID is comparable across cultures, has
high internal and test–retest reliability and is more suitable for
both binary and continuous analysis than other measures of
diabetes distress [31–33]. We used a score of 40 or higher to
define diabetes distress, as this has been found to be around 1
SD above the mean across different studies and has discrimi-
native validity [17, 31]. To account for the possible effect of
‘subthreshold’ symptoms of depression and diabetes distress,
we also used both scales as continuous measures.
For participants with <20% missing data for either PHQ-9
or PAID, we used case mean substitution to impute missing
values. Briefly, case mean substitution imputes missing values
based on the mean scores that are present for that participant
[34]. For any participant, this strategy assumes that the score
on any missing data point is closely related to the scores on the
remaining data points. A major advantage of this technique is
that it uses data provided by a case to estimate its own missing
data, rather than by using data provided by other cases. Case
means substitution has been found to be robust in handling
item-level missingness when 20% of data are missing, wheth-
er in random or systematic patterns [35].
Sample size calculation
We estimated that the minimum clinically significant differ-
ence in change scores in HbA1c in the depressed group should
be 0.5% (5.5 mmol/mol) greater than in the non-depressed
group, with a prevalence ratio of depressive symptoms to the
control group of 1:8 [3]. Using nQuery Advisor, common SD
of 1.77, α = 0.05, 90% power and 30% attrition, the total
sample required was 1738 people.
Statistical analyses
Data were analysed using SPSS 22.0 (IBM Corp. Released
2014; IBM SPSS Statistics, Armonk, NY, USA). To assess for
potential participation bias, we compared participating and
non-participating GP surgeries for list size and index of mul-
tiple deprivation (IMD) score, which is an aggregate measure
of deprivation across seven domains [36]. The full unit postal
code was obtained for each GP surgery and linked with Lower
Super Output Area (LSOA), before being assigned an IMD
rank. From a total of 32,482 LSOAs in England (UK), a rank
of 1 is the most deprived. The baseline characteristics of the
sample itself were then stratified by depressive symptoms and
diabetes distress status and summarised as mean (SD) or
median (interquartile range [IQR]) for normally distributed
or skewed data, respectively, or as a count (%) for categorical
variables. We calculated the Pearson’s coefficient (r) between
depressive symptoms and diabetes distress status at baseline.
For the prospective analysis, we first compared the charac-
teristics of participants who had 2 year HbA1c measured with
those of participants lost to follow-up. We next compared the
proportion of people with depression and diabetes distress at
2 years, stratified by presence or absence of depressive symp-
toms and diabetes distress at baseline. We then compared 1
and 2 year HbA1c and number of incident complications strat-
ified by presence or absence of depressive symptoms and
diabetes distress at baseline. For continuous variables, we
used Student’s t test for normally distributed data and
Mann–Whitney U test for skewed data, and for categorical
variables we used χ2 tests. Our main hypotheses were
assessed using multivariable linear regression for HbA1c as
outcome and multivariable logistic regression for incident
complications as outcome. Finally, we repeated the analyses
using continuous PHQ-9 and PAID scores, which were natural
log-transformed for multivariate analyses.
Diabetologia
Covariates For all multivariate models, we added age, sex
and non-white ethnicity as confounders, as these were associ-
ated with depression, glycaemic control and complications in
the baseline SOUL-D cohort [25], as well as prescription of
hypoglycaemic medications and insulin during follow-up. For
the outcome 2 year HbA1c, we also controlled for baseline
HbA1c to measure worsening of glycaemic control over time.
For complications, we added the following vascular risk fac-
tors to the model: baseline smoking status; baseline systolic
blood pressure (mmHg); baseline fasting serum total choles-
terol (measured using Siemens Advia 2400 Analyzer, detec-
tion limit 0.01mmol/l); baseline HbA1c and baseline BMI (kg/
m2). Finally, we added baseline serum concentration of IL-1
receptor antagonist (IL-1RA) to the model as a confounder, as
this was the inflammatory cytokine that correlated most
strongly with depressive symptoms in a previous study of
the cohort [37]. As described in detail previously [37], serum
IL-1RA was measured after an overnight fast and analysed
using the Randox Evidence Investigator.
Results
Ninety-six out of 138 (69.6%) GP surgeries agreed to partic-
ipate. Participating practices had larger list sizes than those not
participating (10,073 ± 4962 vs 5822 ± 3376, p < 0.001), but
showed no difference in deprivation (IMD rank 7750 ± 4562
vs 8254 ± 4489 p = 0.61). From their diabetes registers, a
target population of 3008 individuals with newly diagnosed
type 2 diabetes were identified during recruitment. Of these,
2406 were potentially eligible and invited to participate and
1735 people consented (Fig. 1).
Of the 1651 people with complete PHQ-9 and PAID as-
sessment at baseline, mean (± SD) age was 56.2 ± 11.1 years,
55.1% were men, 49.1% were of non-white ethnicity and
mean HbA1c was 6.99 ± 1.42% (52.9 ± 10.7 mmol/mol). Of
these, 232 (14.1%) and 111 (6.7%) participants had depressive
symptoms and diabetes distress, respectively, at baseline. Of
those with diabetes distress at baseline, 59 (53.2%) had co-
morbid depressive symptoms, while 59 (25.4%) of those with
depressive symptoms had comorbid diabetes distress. The
resulting correlation between diabetes distress status and de-
pressive symptoms status was r = 0.30 (p < 0.001).
Baseline comparisons
At baseline, participants with depressive symptoms were
younger, more likely to be women, had higher BMI, were
more likely to smoke and had higher baseline IL-1RA con-
centration. Participants with diabetes distress were younger,
more likely to be women and of non-white ethnicity and had
lower systolic BP and higher IL-1RA concentration. There
were no significant differences in glycaemic control, total
cholesterol , diastol ic BP or prescript ion of oral
hypoglycaemic medication when participants were stratified
by depressive symptoms or diabetes distress (Table 1).
Comparison of dropouts with non-dropouts at 2 years
At 2 years, those who had HbA1c measured (n = 1234) vs
those who did not (n = 417) were older (56.8 ± 10.9 years
vs 54.5 ± 11.5 years, p < 0.001), had lower baseline HbA1c
(6.91 ± 1.36% [52.0 ± 10.2 mmol/mol]) vs 7.23 ± 1.56%
[55.5 ± 12.0 mmol/mol], p < 0.001) and were more often of
white ethnicity (53.6% vs 42.9%, p < 0.001). There were no
differences in sex (p = 0.52), baseline depressive symptoms
status (p = 0.064), diabetes distress status (p = 0.37), smoking
status (p = 0.92), prescription of hypoglycaemic medication
(p = 0.19), serum cholesterol (p = 0.67), BMI (p = 0.94),
systolic BP (p = 0.96) or diastolic BP (p = 0.71) (data not
shown).
Course of depressive symptoms and diabetes distress
Fifty-four per cent of people with depressive symptoms at
baseline still had depressive symptoms 2 years later, while
the 2 year prevalence of depressive symptoms (13.8%) was
similar to that seen at baseline. Conversely, only 17.1% of
people with diabetes distress at baseline still had diabetes dis-
tress 2 years later, while the overall prevalence of diabetes
distress fell to 2.4% after 2 years.
HbA1c
In univariate analysis, depressive symptoms at baseline were
not associated with elevated HbA1c after 1 year. Conversely,
depressive symptoms at baseline were associated with elevat-
ed HbA1c after 2 years (Table 2) but this was attenuated after
adjustment for baseline HbA1c, age, sex, ethnicity and diabe-
tes treatments (Table 3). Baseline diabetes distress was not
associated with elevated 1 year or 2 year HbA1c in univariate
or adjusted models (Table 2 and Table 3). Continuous depres-
sive symptoms and diabetes distress were both associatedwith
elevated 2 year HbA1c in univariate analysis. Again, however,
differences were attenuated after adjusting for confounders
(Table 3).
Complications
In univariate analysis, there was a positive association between
baseline depressive symptoms and incident macrovascular
complications. This was largely explained by incident MI, al-
though numbers were low (Table 2). Notably, this association
remained significant (OR 2.78) even after adjustment for age,
sex, ethnicity, vascular risk factors and diabetes treatments, but
was attenuated after adjustment for baseline IL-1RA
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concentration (Table 3). Similar findings were observed for
continuous PHQ-9 score. For diabetes distress, there was no
association with incident macrovascular complications, wheth-
er measured categorically or continuously (Table 2 and
Table 3). In univariate or adjusted models, there was no asso-
ciation between either depressive symptoms or diabetes dis-
tress (measured categorically or continuously) and incident
microvascular complications (Table 2 and Table 3).
Discussion
The SOUL-D cohort is a multi-ethnic, population-based
primary care cohort of people with newly diagnosed
type 2 diabetes, designed and powered to test the effects
of depressive symptoms on proxy markers of cardiovas-
cular risk. Unexpectedly, we found that neither depres-
sive symptoms nor diabetes distress were associated
with worsening HbA1c after 2 years. Despite a low
number of overall events, depressive symptoms at diag-
nosis of type 2 diabetes were associated with greater
risk for macrovascular complications during 2 year fol-
low-up. This occurred independently of age, sex, ethnic-
ity and vascular risk factors but was attenuated after
adjustment for serum IL-1RA. Because all the partici-
pants were recruited within 6 months of diagnosis, con-
founding by duration of diagnosed diabetes was
minimised.
Death (n = 10) 
Patients followed up after 1 year (n = 1421) 
Patients followed up after 2 years  
(n = 1234)
Never responded (n = 34)
Refused/unable to participate (n = 8) 
Patients eligible but not in study  
(n = 601): 
Refused to participate (n = 182)
Invited but not recruited (n = 182) 
Uncontactable (n = 237)
Ineligible (n = 69), withdrew (n = 1) 
GP surgeries not in study (n = 42): 
Attrition during year 1 (n = 230): 
Withdrew or non-contactable (n = 220) 
Attrition during year 2 (n = 187): 
Death (n = 7) 
Withdrew or non-contactable (n = 180) 
Potentially eligible patients identified from GP 
database: type 2 diabetes diagnosed in last 6 
months, aged 18–75 years (n = 2406) 
Patients consenting and seen for baseline visit 
(n = 1805) 
Patients consenting and eligible for study  
(n = 1735) 
Completed baseline depression and diabetes 
distress assessment (n = 1651) 
GP surgeries consenting to participate  
(n = 96) 
All GP surgeries in the south London 
boroughs of Lambeth, Southwark & 
Lewisham invited to participate (n = 138) 
Fig. 1 Flow diagram of
recruitment and attrition over
2 years in the South London
Diabetes Cohort
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Comparison with other studies
Prevalence of diabetes distress and depressive symptoms
The low prevalence of diabetes distress in the SOUL-D cohort
is comparable with other primary care samples [38]. Hospital
cohorts have generally reported much higher prevalence of
diabetes distress [22, 38] but this may relate to a bias towards
people with more complex and complicated diabetes in these
services. Like other studies, we found that depressive symp-
toms and diabetes distress, although correlated, overlapped in
only a minority of individuals [19].
Glycaemic control After adjustment for confounders includ-
ing baseline glycaemic control, neither depressive symptoms
nor diabetes distress were associated with worse glycaemic
control after 2 years in our study. In two previous prospective
Table 2 Outcomes for the SOUL-D cohort
Outcome Total (n)a Depressive
symptoms
(n = 232)
No depressive
symptoms
(n = 1419)
p valueb Diabetes
distress
(n = 111)
No diabetes
distress
(n = 1540)
p valueb
Psychological
Depressive symptoms: PHQ-9 ≥10 at 2 years, n (%)
Yes 162 82 (54.30) 80 (7.82) <0.001 34 (45.95) 128 (11.63) <0.001
No 1012 69 (45.70) 943 (92.18) 40 (54.05) 972 (88.37)
Diabetes distress: PAID ≥40 at 2 years, n (%)
Yes 28 17 (11.64) 11 (1.09) <0.001 12 (17.14) 16 (1.47) <0.001
No 1128 129 (88.36) 999 (98.91) 58 (82.86) 1070 (98.53)
Glycaemic control
1 year HbA1c (%), mean ± SD 1421 6.98 (1.30) 6.89 (1.27) 0.38 6.79 (1.34) 6.91 (1.27) 0.69
1 year HbA1c (mmol/mol), mean ± SD 1421 52.80 (9.83) 51.80 (9.55) 0.38 51.0 (10.3) 51 (9.56) 0.69
2 year HbA1c (%), mean ± SD 1234 7.13 (1.32) 6.89 (1.28) 0.035 7.14 (1.43) 6.91 (1.28) 0.16
2 year HbA1c (mmol/mol), mean ± SD 1234 54.40 (10.07) 51.80 (9.62) 0.035 54.50 (10.87) 52.00 (9.63) 0.16
Complications
Incident MI or CABG by 2 years, n (%)
Yes 24 7 (4.12) 17 (1.58) 0.031 2 (2.50) 22 (1.89) 0.40
No 1221 163 (95.88) 1058 (98.42) 78 (97.50) 1143 (98.91)
Incident stroke by 2 years, n (%)
Yes 12 3 (1.78) 9 (0.84) 0.26 0 (0.00) 12 (1.03) 1.0
No 1230 166 (98.22) 1064 (99.16) 80 (100.00) 1150 (98.97)
Any incident carotid/limb revascularisation or amputation by 2 years, n (%)
Yes 13 2 (1.18) 11 (1.02) 0.86 1 (1.25) 12 (1.03) 0.79
No 1231 168 (98.82) 1063 (98.98) 79 (98.75) 1152 (98.97)
Any incident macrovascular complication by 2 years, n (%)
At least one 40 10 (5.88) 30 (2.79) 0.037 3 (3.75) 37 (3.17) 0.50
None 1207 160 (94.12) 1047 (97.21) 77 (96.25) 1130 (96.83)
Retinopathy present by 2 years, n (%)
Yes 162 27 (16.67) 135 (13.26) 0.24 15 (17.65) 147 (13.42) 0.39
No 1018 135 (83.33) 883 (86.74) 70 (82.35) 948 (86.58)
Neuropathy present by 2 years, n (%)
Yes 113 13 (9.70) 100 (10.49) 0.78 3 (4.23) 110 (10.83) 0.13
No 974 121 (90.30) 853 (89.51) 68 (95.77) 906 (89.17)
Nephropathy present by 2 years (%)
Yes 156 22 (16.06) 134 (15.40) 0.90 12 (17.65) 144 (15.33) 0.48
No 851 115 (83.94) 736 (84.60) 56 (82.35) 795 (84.67)
Any microvascular complication by 2 years, n (%)
At least one 388 55 (30.73) 333 (28.83) 0.60 29 (31.52) 359 (28.90) 0.54
None 946 124 (69.27) 822 (71.17) 63 (68.48) 883 (71.10)
Diabetes treatment
Prescribed insulin at 2 years (%)
Yes 54 14 (7.65) 40 (3.43) 0.008 7 (7.78) 47 (3.73) 0.065
No 1296 169 (92.35) 1127 (96.57) 83 (92.22) 1213 (96.27)
Prescribed diabetes medication at 2 years, n (%)
Yes 894 137 (74.86) 757 (64.87) 0.008 73 (80.22) 821 (65.21) 0.004
No 456 46 (25.14) 410 (35.13) 18 (19.78) 438 (34.79)
The cohort was stratified by: (1) presence/absence of depressive symptoms at baseline as measured by the PHQ-9 and (2) presence/absence of diabetes
distress status at baseline as measured by the PAID scale
a There are missing data for some variables resulting in different percentages; the total number of individuals for each variable is therefore given
b Parametric continuous data were compared using Student’s t test; non-parametric continuous data were compared using Mann–Whitney U test;
categorical variables were compared using χ2 tests
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studies of depressive symptoms, but not diabetes distress, any
differences in glycaemic control were likewise negated by
adjusting for baseline glycaemic control [10, 11]. In comparing
diabetes distress and depressive symptoms, a study of 3305
Japanese individuals with type 2 diabetes reported that diabe-
tes distress was associated with greater odds of poor glycaemic
control (HbA1c ≥8%) than depressive symptoms [26].
However, that cohort differed from ours by the long-
established diabetes of its participants (mean 13.8 years, 41%
receiving insulin therapy). Likewise, a study of 627 individuals
in a secondary care setting in the Netherlands reported that
diabetes distress was more strongly associated with glycaemic
control than depressive symptoms [22]. Both studies were
limited by their cross-sectional design. Only one previous
observational study in a type 2 diabetes cohort has compared
depressive symptoms and diabetes distress for their prospective
associations with glycaemic control [9]. In this study, Fisher
and colleagues reported a significant association between
diabetes distress and worsening glycaemic control, an associa-
tion not demonstrated for depressive symptoms. Although
comparable with ours in recruiting a multi-ethnic, primary care
cohort, the Fisher study was limited by a smaller sample size
(n = 506), shorter follow-up, longer mean duration of diabetes
(8.1 years) and lack of data on incident complications.
Complications A previous meta-analysis found that depres-
sive symptoms were associated with both macrovascular and
microvascular complications in individuals with type 1 and
type 2 diabetes [4]. Several studies have demonstrated that
depressive symptoms are associated with incident stroke in
individuals with type 2 diabetes [39, 40]. For diabetes distress,
one previous prospective cohort study reported that general
distress (rather than diabetes-specific distress) was associated
with a 1.7-fold increased risk of cardiovascular disease over
time [41]. To date, however, we are not aware of any study that
has investigated the prospective association between diabetes
distress and depressive symptoms with incident complications.
Interpretation
Our findings were unexpected. If the effect of depression re-
sulted from a behavioural mechanism such as self-neglect and
poor adherence to medication, it is reasonable that the conse-
quences would manifest as poorer glycaemic control within
the first 2 years of diagnosis. We did not observe this but we
did observe an effect of depression on macrovascular disease.
While this may reflect pre-existing vulnerability to cardiovas-
cular disease, it could be that depression is also a proxymarker
for future cardiovascular risk. Although the number of events
was low, we found that the association between depressive
symptoms and incident macrovascular disease occurred inde-
pendently of other known vascular risk factors and glycaemic
control. When we further controlled for baseline IL-1RA
concentration, the association between depressive symptoms
and macrovascular disease was attenuated, pointing towards a
possible inflammatory mechanism. There is compelling evi-
dence that elevated inflammation is on the causal pathway for
the pathogenesis of type 2 diabetes and subsequent
macrovascular complications [42, 43]. Intervention studies
that would allow testing of the directionality of the association
between depressive symptoms, inflammation and biomedical
outcomes are needed. Future studies should take into account
wider contextual factors, such as frequency of contact with
healthcare professionals, access to diabetes education and ac-
cess to mental health services.
Limitations
Our study has several limitations. Despite its inner-city setting
with high overall levels of deprivation, we were able to
achieve nearly 70% GP participation. Although there is a risk
of selection bias compared with those not participating, there
was no difference in deprivation indicators between those sur-
geries participating and those not. There is a risk of attrition
bias due to dropout at 2 years, although neither of the explan-
atory variables were significant predictors of attrition. The low
prevalence of diabetes distress may have restricted power
when testing its associations. We used a self-report measure
of depressive symptoms, which is well suited to epidemiolog-
ical studies but will likely result in more cases of depressive
symptoms when compared with a diagnostic interview.
Although our findings were supported by both categorical
and continuous measures of depressive symptoms, the overall
number of macrovascular events during follow-up was low.
We did not control for previous cardiovascular disease as this
variable may be collinear, being on the causal pathway to
future cardiovascular disease, and addition of this covariate
would have reduced the number of events per cell. Likewise,
because of low numbers of events, effect modification analy-
sis stratified by inflammation status was not possible and IL-
1RA could only be included as a confounder in the analyses.
The latter two limitations will only be overcome with longer-
term follow-up, by which time a greater number of
macrovascular events is expected.
Conclusion
We conclude from our study that neither depressive symptoms
nor diabetes distress is associated with worsening glycaemic
control over 2 years. Conversely, depressive symptoms are
independently associated with increased risk of incident
macrovascular disease in the first 2 years of type 2 diabetes.
As the overall number of events was low, longer-term pro-
spective studies and intervention studies are now needed to
test whether depressive symptoms at diagnosis of type 2 dia-
betes are a modifiable target.
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